Abstract Aim ProTetanus immunoassay is a bedside test used to determine if a patient has tetanus antibodies. It has been proven to be sensitive and specific at determining tetanus vaccination status. Although it is available on NHS Supply Chain, it is not widely used. Our aim was to prevent unnecessary Revaxis booster administrations as well as reduce the associated cost. Method Using a visual protocol based on trust and NICE guidelines, we determined which patients with tetanus prone wounds would otherwise require vaccination due to uncertainty of their previous immunisation. ProTetanus test was used to assess their immune status. If no immunity was shown, a booster was administered. A simple questionnaire was used to collect data on the test result, ease of use, and time required to perform the test. Results 18 responses were recorded over 2 months. 2 patients were unnecessarily tested but all patients were treated correctly. In terms of cost efficiency, Revaxis costs £10.16 per vial and ProTetanus £4.15 per test. Therefore, a negative test costs £14.31 and a positive test costs £4.15. In our unit, without ProTetanus, 17 doses of Revaxis would have been administered, costing £172.72. With ProTetanus, 8 doses were prevented, dropping the cost to £161.99. Conclusions The introduction of ProTetanus, prevents unnecessary tetanus booster administrations for our patients, improves the level of clinical care, and provides a cost reduction. We have demonstrated that the use of the immunoassays becomes easier with use and minimise reliance on registered nurses. We strongly advocate its use into other departments and units.